Convenient once-daily tablet
- The recommended Tarceva dose is 150 mg once daily1
- Tarceva is available in tablets of three different strengths, 150 mg, 100 mg and 25 mg1*
*25 mg tablet not available in all countries
Multiple tablet strengths allow for dose titration without discontinuation
If patients experience intolerable adverse events, e.g. severe skin reactions, diarrhea unresponsive to loperamide or that causes dehydration, or severe liver function test abnormalities, consider dose reduction or interruption of Tarceva.1
The following dose modification guidelines were specified in the pivotal phase III trial, for grade ≥3 rash or diarrhea not able to be medically managed:1,2
- Withhold therapy until symptom severity is returned to grade ≤12
- Resume therapy at a dose 50 mg lower than the original dose1
Tarceva therapy should be suspended if interstitial lung disease is suspected, and discontinued if confirmed.1
Do not take with food
Food consumption substantially increases the bioavailability of Tarceva and may increase the risk of adverse events.1–3
- Tarceva should be taken at least one hour before or two hours after the ingestion of food1,2
- Taking Tarceva on an empty stomach helps ensure consistent drug plasma levels1,2
Precautions with Tarceva
- Woman of childbearing potential must be advised to avoid pregnancy while on Tarceva1
- Current smokers should be advised to stop smoking, as plasma concentrations in smokers are reduced compared with non-smokers1
Concomitant treatment with CYP3A4 inhibitors and inducers should be avoided
- Potent inducers of CYP3A4 may reduce the efficacy of Tarceva1
- Potent inhibitors of CYP3A4 may lead to increased toxicity1
- Tarceva® (erlotinib) Summary of Product Characteristics, F. Hoffmann-La Roche Ltd, 2011.
- Roche, data on file.
- Hidalgo M, Sui LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267–3279.